Societal Costs of First-Incident Ischemic Stroke in Patients with Atrial Fibrillation-A Danish Nationwide Registry Study.

@article{Jakobsen2016SocietalCO,
  title={Societal Costs of First-Incident Ischemic Stroke in Patients with Atrial Fibrillation-A Danish Nationwide Registry Study.},
  author={Marie Jakobsen and Christophe Kolodziejczyk and Eskild Klausen Fredslund and Peter Bo Poulsen and Lars Dybro and S{\o}ren Paaske Johnsen},
  journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
  year={2016},
  volume={19 4},
  pages={
          413-8
        },
  url={https://api.semanticscholar.org/CorpusID:42044120}
}
View on PubMed
valueinhealthjournal.com
16 Citations
Background Citations
4
Methods Citations
1
Results Citations
1

16 Citations

Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation – a nationwide cohort study

The societal costs attributable to major bleeding events in patients with AF are significant and intracranial haemorrhages are most costly to society with average costs of similar magnitude as the costs of ischemic stroke.

Cost of illness of atrial fibrillation: a nationwide study of societal impact

The societal costs attributable to atrial fibrillation are significant and reducing the need for hospitalizations, in particular from stroke, is a key factor in controlling the costs.

The budget impact of implementing atrial fibrillation-screening in European countries

Though the initial cost of screening and more frequent use of oral anti-coagulants will increase the healthcare payers’ costs, introducing population screening for AF will result in savings of stroke-related costs.

The Cost-Effectiveness of One-Time Opportunistic Screening for Atrial Fibrillation in Different Age Cohorts of Inhabitants in Denmark Aged 65 Years and Above. A Markov Modelled Analysis.

The present study showed that one-time opportunistic screening for AF was more costly, but also more effective compared to a no-screening alternative, and support a potential implementation of opportunistic Screening for AF at the general practitioner level in Denmark.

ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study.

Short-term societal economic burden of first-incident type 2 diabetes-related complications – a nationwide cohort study

Short-term excess costs of treating specific first-incident diabetes-related complications are massive for society and the importance of strengthening primary prevention within type 2 diabetes to minimize the risk of developing costly diabetes- related complications is highlighted.

Systematic review of societal costs associated with stroke, bleeding and monitoring in atrial fibrillation.

Limited data were available on societal costs in atrial fibrillation and further research is warranted, but the contribution of indirect costs to the total was marginal during acute treatment but substantially increased 2 years after stroke and bleeding events.

Cost Effectiveness of Patient Self-Managed Warfarin Compared with Direct Oral Anticoagulants in Atrial Fibrillation: An Economic Evaluation in a Danish Healthcare Sector Setting

The present study found that PSM is dominant (i.e., both more effective and cost saving) compared with DOACs, adding to the scarce evidence of the comparative cost effectiveness of PSM andDOACs in NVAF.

Excess costs of non-infectious comorbidities among people living with HIV – estimates from Denmark and Sweden

The high prevalence of comorbidities in the HIV-infected population is associated with substantial excess costs, and Focus on primary and secondary prophylactic interventions is warranted.

Direct medical costs of cardiovascular diseases: Do cost components vary according to sex and age?

CVD-associated direct medical costs varied by components, sex, age, and follow-up years, with either medication costs or physician fees being the predominant components, depending on the specific subgroups.

31 References

The effect of atrial fibrillation on stroke-related inpatient costs in Sweden: a 3-year analysis of registry incidence data from 2001.

AF-related strokes are associated with higher 3-year inpatient costs than non-AF strokes when controlling for factors such as case fatality rates, other risk factors for stroke, and age.

The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study.

Medical care for stroke patients with AF is associated with higher costs compared with those without AF; this is explained mainly by confounding factors and driven essentially by a significant difference in acute hospitalization costs.

Population-Based Study of Acute- and Long-Term Care Costs after Stroke in Patients with AF

Although annual post acute phase hospital and primary health-care costs in stroke patients with prior atrial fibrillation were not significantly different to those incurred before the stroke, long-term nursing/residential care costs were substantial.

Acute Hospital, Community, and Indirect Costs of Stroke Associated With Atrial Fibrillation: Population-Based Study

In a population-based prospective study of incident and recurrent stroke treated in hospital and community settings, AF-stroke was associated with substantially higher total, acute hospital, nursing home, and general practitioner costs per patient.

Hospital Costs Associated With Atrial Fibrillation for Patients With Ischemic Stroke Aged 18–64 Years in the United States

AFib increased the hospital cost of ischemic stroke substantially and the AFib-associated costs for repeat stroke admissions were not significantly higher than for non-AFib patients, except for those aged 55 to 64 years ($3537).

Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study

CHA2DS2-VASc performed better than CHADS2 in predicting patients at high risk, and those categorised as low risk by CHA2 DS2- VASc were truly at low risk for thromboembolism.

Age-Specific Incidence, Outcome, Cost, and Projected Future Burden of Atrial Fibrillation–Related Embolic Vascular Events: A Population-Based Study

Numbers of AF-related incident ischemic strokes at age ≥80 years have trebled over the last 25 years, despite the introduction of anticoagulants, and are projected to treble again by 2050, along with the numbers of systemic emboli.

Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry

This study shows that the validity of the diagnosis of atrial fibrillation and/or AFL is high and may be used for registry-based studies and was not reliable to distinguish between cases of AF and AFL.

Predictive value of stroke and transient ischemic attack discharge diagnoses in The Danish National Registry of Patients.

Anticoagulation in atrial fibrillation

The rationale for anticoagulant therapy in patients with atrial fibrillation; risk stratification for treatment; available agents; the appropriate implementation of these agents; and additional, specific clinical considerations for treatment are discussed.

Related Papers

Showing 1 through 3 of 0 Related Papers